Bridgeway Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-148,200
| Closed | -$865K | – | 1456 |
|
|
2022
Q4 | $865K | Hold |
148,200
| – | – | 0.02% | 765 |
|
|
2022
Q3 | $993K | Hold |
148,200
| – | – | 0.03% | 741 |
|
|
2022
Q2 | $624K | Buy |
148,200
+55,000
| +59% | +$218K | 0.01% | 831 |
|
|
2022
Q1 | $314K | Sell |
93,200
-55,000
| -37% | -$174K | 0.01% | 1066 |
|
|
2021
Q4 | $467K | Hold |
148,200
| – | – | 0.01% | 1000 |
|
|
2021
Q3 | $485K | Buy |
148,200
+35,100
| +31% | +$123K | 0.01% | 1042 |
|
|
2021
Q2 | $477K | Buy |
+113,100
| New | +$479K | 0.01% | 1077 |
|
|
2020
Q2 | – | Sell |
-57,700
| Closed | -$510K | – | 1424 |
|
|
2020
Q1 | $510K | Sell |
57,700
-25,000
| -30% | -$247K | 0.01% | 757 |
|
|
2019
Q4 | $763K | Sell |
82,700
-62,400
| -43% | -$442K | 0.01% | 808 |
|
|
2019
Q3 | $853K | Hold |
145,100
| – | – | 0.01% | 765 |
|
|
2019
Q2 | $1.74M | Sell |
145,100
-50,500
| -26% | -$543K | 0.02% | 581 |
|
|
2019
Q1 | $2.36M | Sell |
195,600
-20,700
| -10% | -$305K | 0.03% | 469 |
|
|
2018
Q4 | $2.71M | Hold |
216,300
| – | – | 0.04% | 385 |
|
|
2018
Q3 | $3.21M | Hold |
216,300
| – | – | 0.03% | 455 |
|
|
2018
Q2 | $3.64M | Buy |
216,300
+51,300
| +31% | +$996K | 0.04% | 406 |
|
|
2018
Q1 | $3.78M | Sell |
165,000
-2,100
| -1% | -$46.7K | 0.04% | 366 |
|
|
2017
Q4 | $4.32M | Buy |
167,100
+125,000
| +297% | +$2.52M | 0.05% | 332 |
|
|
2017
Q3 | $621K | Hold |
42,100
| – | – | 0.01% | 1027 |
|
|
2017
Q2 | $587K | Sell |
42,100
-28,200
| -40% | -$416K | 0.01% | 1035 |
|
|
2017
Q1 | $1.2M | Buy |
70,300
+42,100
| +149% | +$505K | 0.01% | 753 |
|
|
2016
Q4 | $290K | Hold |
28,200
| – | – | ﹤0.01% | 1226 |
|
|
2016
Q3 | $285K | Hold |
28,200
| – | – | ﹤0.01% | 1253 |
|
|
2016
Q2 | $317K | Sell |
28,200
-15,300
| -35% | -$195K | ﹤0.01% | 1208 |
|
|
2016
Q1 | $594K | Sell |
43,500
-200
| -0.5% | -$2.88K | 0.01% | 970 |
|
|
2015
Q4 | $829K | Buy |
43,700
+200
| +0.5% | +$4.35K | 0.02% | 839 |
|
|
2015
Q3 | $817K | Hold |
43,500
| – | – | 0.02% | 820 |
|
|
2015
Q2 | $648K | Hold |
43,500
| – | – | 0.01% | 949 |
|
|
2015
Q1 | $659K | Hold |
43,500
| – | – | 0.01% | 979 |
|
|
2014
Q4 | $579K | Buy |
43,500
+30,000
| +222% | +$387K | 0.01% | 989 |
|
|
2014
Q3 | $170K | Hold |
13,500
| – | – | ﹤0.01% | 1359 |
|
|
2014
Q2 | $136K | Buy |
+13,500
| New | +$130K | ﹤0.01% | 1377 |
|
Bridgeway Capital Management's CNCE Position: Q1 2023 in Review
Bridgeway Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 148,200 shares — an estimated $865K sold.
Bridgeway Capital Management first reported a position in CNCE in Q2 2014 and held it in 31 quarters. The position peaked at $4.32M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Bridgeway Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Bridgeway Capital Management sold 148,200 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $865K.
- Bridgeway Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 31 quarters.
- Bridgeway Capital Management's Concert Pharmaceuticals, Inc. position peaked at $4.32M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.